Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers;Occurrence of adverse events (AEs);Occurrence of Adverse Events of Special Interest (AESIs).;Occurrence of New-Onset Chronic Medical Condition (NOCMCs).;Occurrence of Related Medically attended adverse events (MAAEs).;Occurrence of Serious Adverse Events (SAEs).;Occurrence of solicited reactogenicity adverse events (AEs);Response rate of SARS-CoV-2 specific antibody binding and neutralization titers

Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers;Occurrence of adverse events (AEs);Occurrence of Adverse Events of Special Interest (AESIs).;Occurrence of New-Onset Chronic Medical Condition (NOCMCs).;Occurrence of Related Medically attended adverse events (MAAEs).;Occurrence of Serious Adverse Events (SAEs).;Occurrence of solicited reactogenicity adverse events (AEs);Response rate of SARS-CoV-2 specific antibody binding and neutralization titers

Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers;Occurrence of Adverse Events (AEs) following delayed booster vaccination;Occurrence of Adverse Events of Special Interest (AESIs) after last dose on study.;Occurrence of local solicited reactogenicity adverse events (AEs);Occurrence of Related Medically attended adverse events (MAAEs) after last dose on study.;Occurrence of Serious Adverse Event (SAEs) after last dose on study.;Response rate of SARS-CoV-2 specific antibody binding and neutralization titers

Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers;Occurrence of Adverse Events (AEs) following delayed booster vaccination;Occurrence of Adverse Events of Special Interest (AESIs) after last dose on study.;Occurrence of local solicited reactogenicity adverse events (AEs);Occurrence of Related Medically attended adverse events (MAAEs) after last dose on study.;Occurrence of Serious Adverse Event (SAEs) after last dose on study.;Response rate of SARS-CoV-2 specific antibody binding and neutralization titers